Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
Journal of Clinical Endocrinology & Metabolism · Vol. 91(3) · pp. 799–805 · 2006
Phase 1/2 human clinical trial demonstrating that CJC-1295 (DAC-GRF) produces sustained GH and IGF-1 elevation for up to 6 days after a single injection. Establishes the pharmacokinetic basis for weekly CJC-1295 dosing protocols used in GH optimization.
Citation
Key Findings
Single CJC-1295 injection elevated mean GH levels 2–10 fold for 6 days
IGF-1 levels increased 1.5–3 fold and remained elevated for up to 2 weeks
Drug Affinity Complex (DAC) technology extends half-life from minutes to days
Dose-dependent GH and IGF-1 response with good tolerability
No significant adverse effects on cortisol, prolactin, or thyroid hormones
Methodology
Phase 1/2 dose-escalation study in healthy adults. Serial GH and IGF-1 measurements over 28 days post-injection. Safety and tolerability assessment.
Limitations
Small sample size (n=65). Long-term effects of sustained GH elevation not characterized. Optimal combination with GHRPs not studied in this trial.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor 1 Secreti…
2006 · Strong Evidence
Ipamorelin, the First Selective Growth Hormone Secretagogue
1998 · Strong Evidence
Ipamorelin, the First Selective Growth Hormone Secretagogue
1998 · Strong Evidence
Regulation of Muscle Mass by Follistatin and Activins
2001 · Moderate Evidence
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment